Consensus Statement

J Vet Intern Med 2016;30:15–35

Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements.

Update on Canine and Feline Blood Donor Screening for Blood-Borne Pathogens

K.J. Wardrop, A. Birkenheuer, M.C. Blais, M.B. Callan, B. Kohn, M.R. Lappin, and J. Sykes

An update on the 2005 American College of Veterinary Internal Medicine (ACVIM) Consensus Statement on blood donor infectious disease screening was presented at the 2015 ACVIM Forum in Indianapolis, Indiana, followed by panel and audience discussion. The updated consensus statement is presented below. The consensus statement aims to provide guidance on appropriate blood-borne pathogen testing for canine and feline blood donors in North America.

Key words: Blood donor testing; Transfusions.

A blood or blood component transfusion generally is a life-saving measure, but absolute safety can never be guaranteed. In addition to immune-mediated reactions caused by infusion of allogeneic cells or proteins, blood-borne pathogens can be transmitted by transfusion, potentially causing disease in the transfused recipient. In an effort to minimize pathogen transmission, all blood donors should be appropriately screened for infectious agents.

The following recommendations are based on the information available at the time of this writing. For clarity, the consensus panel subdivided pathogens into the following categories for the dog and cat:

1. Vector-borne pathogens—testing recommended
2. Non vector-borne pathogens—testing recommended
3. Other pathogens—testing not recommended

Pathogens for which testing is recommended met at least three of the following criteria: (1) the pathogen has been documented to cause clinical infection in recipients after blood transmission, (2) the pathogen is capable of causing subclinical infection such that carriers might inadvertently be identified as healthy blood donors, (3) the pathogen can be detected using culture or molecular methods from the blood of an infected animal, and (4) the resultant infection in the recipient has the potential to cause life-threatening illness and be difficult to eliminate with antimicrobial drugs. Using optimal standards (Tables 1 and 2, see below), testing also is recommended for those pathogens that can be experimentally transmitted by blood transfusion, even though clinical illness after transfusion has not been described.

The panel separated screening recommendations into optimal and minimal standards, which are

---

From the Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA (Wardrop); the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC (Birkenheuer); the Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Montreal, QC (Blais); the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA (Callan); the Clinic of Small Animals, Faculty of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany (Kohn); the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (Lappin); and the Department of Medicine and Epidemiology, University of California, Davis, CA (Sykes).

Corresponding author: K.J. Wardrop, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99164-7060; e-mail: kpw@vetmed.wsu.edu

Submitted November 5, 2015; Revised November 23, 2015; Accepted November 23, 2015.

Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1111/jvim.13823

Abbreviations:

| Acronym | Abbreviation |
|---------|--------------|
| BAPGM   | Bartonella alpha proteobacteria growth medium |
| FeLV    | feline leukemia virus |
| FIV     | feline immunodeficiency virus |
| IFA     | immunofluorescent antibody |
| PCR     | polymerase chain reaction |
| RSAT    | rapid slide agglutination test |
| WNV     | West Nile virus |

---

1. Vector-borne pathogens—testing recommended

2. Non vector-borne pathogens—testing recommended

3. Other pathogens—testing not recommended
Table 1. Recommendations for screening of canine blood donors for blood-borne pathogens.

| Agent                  | Optimal Standards | Minimal Standards | Comments                                                                                                                                 |
|------------------------|-------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| **Vector-borne**       |                   |                   |                                                                                                                                         |
| **pathogens—testing recommended** |                   |                   |                                                                                                                                         |
| *Anaplasma*            |                   |                   |                                                                                                                                         |
| *phagocytophilum*      | Seronegative and  | PCR negative dogs | In areas endemic for *Ixodes* spp., identification of seronegative donors may be difficult. Therefore, use of seropositive but PCR negative dogs as donors is considered acceptable in this situation. Seronegative dogs are rarely PCR positive and so serological testing alone could be considered if serologic testing is more economical or yields more rapid turnaround time than PCR. |
| *Anaplasma platys*     | Seronegative and  | PCR negative dogs | In areas endemic for *Rhipicephalus* tick spp., identification of seronegative donors may be difficult. Therefore, use of seropositive but PCR negative dogs as donors is considered acceptable in this situation. Seronegative dogs are rarely PCR positive and so serological testing alone could be considered if serologic testing is more economical or yields more rapid turnaround time than PCR. |
| *Babesia canis vogeli* | Seronegative and  | PCR negative      | High risk dogs include greyhounds and those with a history of exposure to *Rhipicephalus* ticks.                                          |
| *Babesia gibsoni*      | Seronegative and  | PCR negative      | High risk dogs include pitbull terriers and donors that have had a history of aggressive interactions with pitbull terriers.           |
| Other *Babesia* spp.   | PCR negative      | PCR negative dogs | Serology is not available; distribution is limited and so screening could be considered optional.                                     |
| *Bartonella henselae*  | Seronegative and  | PCR negative      | Serology is negative in over 50% of clinical cases and should not be used alone for screening. PCR without BAPGM culture enrichment is insensitive for detection of *Bartonella* bacteremia in dogs, but the overall prevalence of infection in dogs is low. When testing with BAPGM culture-PCR is not practical because of expense and/or turnaround time, either serology combined with PCR or PCR alone could be considered. |
| *Bartonella vinsonii*  | Seronegative and  | PCR negative      | See *Bartonella henselae*                                                                                                               |
| var. *berkhoffi*       | BAPGM culture-PCR | No screening      | Serologic assays are species-specific and are not available for many species; most are not as prevalent as *B. henselae* or *B. vinsonii* and their pathogenicity is less well established. |
| Other *Bartonella* spp.| BAPGM culture-PCR | No screening      | All donors should be screened. Seronegative dogs are rarely PCR positive and so serological testing alone could be considered if serologic testing is more economical or yields more rapid turnaround time than PCR. In contrast to *A. phagocytophilum*, seropositive dogs should not be used as donors, as *E. canis* is a significant pathogen and PCR assays are insensitive for ruling out the presence of infection in chronically infected dogs. |
| *Ehrlichia canis*      | Seronegative and  | Seronegative dogs  | High risk areas are the southeastern United States and the mid-Atlantic states. Not all serological assays are known to detect antibodies to *E. chaffeensis.* |
| *Ehrlichia chaffeensis*| Seronegative and  | PCR negative      | High risk areas are the southeastern United States and the mid-Atlantic states. Not all serological assays are known to detect antibodies to *E. chaffeensis.* |

(continued)
| Agent                  | Optimal Standards | Minimal Standards | Comments                                                                                                                                                                                                 |
|------------------------|-------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| *Ehrlichia ewingii*    | Seronegative and PCR negative dogs | Seronegative dogs or PCR negative dogs in high risk areas; no screening in low risk areas | High risk areas are those endemic for *Amblyomma americanum* ticks. Not all serological assays are known to detect antibodies to *E. ewingii*.                                                                 |
| *Hepatozoon canis*    | PCR negative dogs  | No screening      | Serologic assays are not available for routine diagnosis in the United States. Testing using PCR is strongly recommended in endemic regions (south-eastern and south-central United States). Natural transmission requires ingestion of an infected tick; transmission by blood transfusion has not been documented. |
| *Leishmania donovani* | Seronegative and PCR negative dogs | Seronegative and PCR negative in high risk dogs; no screening in low risk dogs | High-risk dogs include foxhounds, foxhound/crosses, or dogs living in or traveling to endemic areas.                                                                                                       |
| *Mycoplasma haemocanis* | PCR negative dogs | PCR negative dogs | Serologic assays are not available. Cytologic examination of blood smears is not accurate. The organism can be a primary pathogen and so PCR screening is recommended.                                          |
| "*Candidatus Mycoplasma haematoparvum*" | PCR negative dogs | No screening | Serologic assays are not available. Cytologic examination of blood smears is not accurate. The organism is not considered a primary pathogen and so screening could be considered optional. |
| *Neorickettsia risticii* | PCR negative dogs | No screening | Serologic assays are not available. The organism has only rarely been detected in dogs.                                                                                                                        |
| *Rickettsia felis*     | PCR negative dogs  | No screening      | Serologic assays are not available. While *R. felis* has been detected in the blood of dogs with heavy flea infestations, it has not been associated with disease in dogs and so screening could be considered optional. |
| *Trypanosoma cruzi*   | Seronegative dogs  | No screening      | Transfusion-related infections have not been reported in dogs and so screening could be considered optional. Screening is primarily recommended in endemic areas (southern United States, primarily southeastern Texas) |
| **Non vector-borne pathogens—testing recommended** | Seronegative dogs | No screening | A single negative serology result is considered sufficient in neutered donors, but screening should be repeated in sexually active dogs. Healthy neutered dogs that are not from a kennel and without a breeding history are unlikely to be exposed. |
| **Brucella canis**     | Seronegative dogs  | No screening      | Transfusion-related infections not reported *Neorickettsia helminthoeca* has not been documented to cause persistent subclinical infections and so is not likely to be transfused from a healthy dog. |
| **Borrelia burgdorferi** | No screening | No screening | *Rickettsia rickettsii* has not been documented to cause persistent subclinical infections and so is not likely to be transfused from a healthy dog. |
| **Neorickettsia helminthoeca** | No screening | No screening | No persistent infections; no transfusion-related infections described.                                                                                                                                   |

*See the text for further discussion of geographic distribution and risk factors.

*See the text for further discussion of specific tests.
Table 2. Recommendations for screening of feline blood donors for blood-borne pathogens.

| Agent b | Optimal Standards | Minimal Standards b | Comments |
|---------|-------------------|---------------------|----------|
| **Vector-borne pathogens—testing recommended** | | | |
| *Anaplasma phagocytophilum* | Seronegative and PCR negative cats | PCR negative cats. Seronegative cats are an acceptable alternative if serologic testing is more economical or yields more rapid turnaround time than PCR. | Seropositive, PCR-negative cats may be used in endemic regions if no other suitable donor can be identified. |
| *A. platys* | PCR negative cats | No screening | There is no valid serological assay for cats. Infection of cats has only been occasionally documented. |
| *Bartonella henselae* | Seronegative and PCR or culture negative cats | PCR negative cats | Around 70% of seropositive cats are PCR negative. In endemic areas, finding seronegative cats can be difficult and so use of seropositive, PCR negative cats may be needed. |
| Other *Bartonella* spp. | PCR negative cats | No screening | Serologic assays are species-specific, and assays are not readily available for many species. *B. henselae* appears to be the most pathogenic species. |
| *Cytauxzoon felis* | PCR negative cats | No screening | Serology is not available. Testing using PCR is strongly recommended for cats with access to the outdoors that reside in endemic regions; cytologic examination of blood smears is not accurate. |
| *Ehrlichia canis* and *E. canis*-like | PCR negative cats | No screening | Infection of cats is extremely rare. |
| *Mycoplasma haemofelis* | PCR negative cats | PCR negative cats | Serologic assays are not available. Cytologic examination of blood smears is not accurate. The organism is a major primary pathogen and so PCR screening is always optimal. |
| “*Candidatus Mycoplasma haemominutum*” | PCR negative cats | No screening | Serologic assays are not available. Cytologic examination of blood smears is not accurate. The organism is not considered a primary pathogen and is highly prevalent in the cat population, so screening could be considered optional. |
| “*Candidatus Mycoplasma turicensis*” | PCR negative cats | No screening | Serologic assays are not available. “*Candidatus M. turicensis*” has never been detected using cytologic examination of blood smears, and cytology is not accurate for identification of hemoplasmas. The organism is not considered a primary pathogen and so screening could be considered optional. |
| *Neorickettsia risticii* | PCR negative cats | No screening | Serology is not available. The organism has only rarely been associated with infection in cats. |
| **Non vector-borne pathogens—testing recommended** | | | |
| Feline leukemia virus | Antigen negative and proviral DNA PCR negative cats | Antigen negative cats | Clinically validated proviral DNA assays are not routinely available in the United States. |
| Feline immunodeficiency virus | Antibody negative cats | Antibody negative cats | It is currently not possible to accurately differentiate between an infected cat and an FIV-vaccinated cat and so all positive cats should be excluded as donors. |
included in the text and in Tables 1 and 2. These recommendations were made using available evidence from human and veterinary medical literature, and, where evidence was lacking, the combined opinions and clinical experiences of the panel members were used to develop recommendations. The goal of the optimal standards is to minimize risk to the best of our ability by application of currently available diagnostic tests. However, the panel acknowledged that application of all diagnostic tests might not be relevant for all geographic locations and donor backgrounds (eg, breed, environment) and some diagnostic tests have limited availability or could be cost prohibitive for some programs. Therefore, the minimal standards were developed taking into account these factors. In some cases, this approach unfortunately could result in movement of infected animals into the donor pool. The panel also discussed alternative acceptable strategies for geographic regions where the prevalence of infection may be high and identification of suitable donors is difficult as well as screening of potential donors when blood is required in an emergency situation and time does not permit thorough screening before donation. An apparently healthy donor may be acceptable in that situation given the low risk of transmission of infection when weighed alongside a high risk of death of the recipient in the absence of blood product transfusion. However, preemptive identification and screening of healthy blood donors remains an important strategy of safe blood banking.

In human blood collections, individual units of whole blood collected for transfusion purposes typically are screened for infectious agents. By contrast, economic factors in veterinary medicine often limit testing to the blood donor animals themselves. The consensus panel recommends a minimum of yearly testing of blood donors, with consideration of more frequent retesting for some pathogens in endemic areas and in donors with repeated exposure to risk factors (eg, tick exposure). The consensus panel agreed that prevention of infections by proper handling and storage of blood products techniques also should be considered, recommendations for which are included in the consensus statement.

### General Comments on Infectious Agent Screening

Screening of blood donors should always follow a thorough history and physical examination to evaluate for factors that may make the animal a poor blood donor choice (see donor selection and care section). No tests for infectious agents have 100% analytical or clinical sensitivity and specificity. When screening for bloodborne pathogens in a potential blood donor, the test or tests with the greatest analytical sensitivity should be used. However, in situations where the prevalence of infection is low (as is the case for some pathogens in healthy animals compared with sick animals), positive results are more likely to represent false positives than in regions of high prevalence (low positive predictive value), and consideration should be given to verifying such positive results with a second test, preferably using a reference laboratory. Also, testing decisions should be based on the value of individual tests for a given pathogen, rather than choosing tests simply because they are present in blood donor panels offered by commercial laboratories.

Following is a brief discussion of the basic utility and limitations of these tests:

#### Organism or Antigen Tests

**Light Microscopy.** Documentation of an infectious agent in blood smears by cytologic examination requires skilled personnel, is time consuming (an adequate blood film examination can take 20–30 minutes), and lacks sensitivity for most pathogens. False positives can also occur, such as when staining artifacts are confused with micro-organisms. Therefore, cytologic examination of blood smears is not recommended as the sole means of screening blood donors for infection.

**Culture.** Positive blood culture results indicate the presence of cultivable bacteria in the blood. Although transient bacteremia can occur in healthy animals after disruption of mucosal barriers, transfusion of blood from animals with transient bacteremia has not been documented to cause disease in a recipient. Therefore, routine blood culture generally is not indicated for screening potential blood donors, with rare exceptions (see Bartonella section). In transfusion medicine, routine
blood culture is more appropriate for screening individual units of blood for bacteria if contamination is suspected.

**Serum Antigen Tests.** Assays that detect antigens of several blood-borne pathogens in whole blood or serum are commercially available. *Dirofilaria immitis* (dogs and cats) and feline leukemia virus (FeLV) antigen tests are used most frequently for donor screening and health assessment. Point-of-care tests are available for both organisms, with the potential for inaccurate results from operator error is small.

**Molecular Assays.** Because the immune system generally clears nonviable microbes quickly, amplification of specific microbial nucleic acids using assays like polymerase chain reaction (PCR) generally indicates the presence of viable microbes, provided laboratory quality assurance is high. These techniques can provide high analytic sensitivity and specificity and the potential to rapidly test for more than 1 pathogen. Disadvantages include the current lack of point-of-care nucleic acid-based assays in veterinary medicine; lack of standardization of assays among laboratories, which results in variable sensitivities and specificities; lack of assay availability for some infectious agents; and expense. Also, high analytical sensitivity of a PCR assay does not necessarily imply high clinical sensitivity. In other words, an assay may detect minute quantities of DNA in the laboratory but have poor sensitivity for detection of a pathogen in a blood specimen. Most PCR assays utilize 10–200 μL of blood, and animals can receive over 10,000 times that volume during a transfusion. Although most molecular assays have high analytical sensitivity, these assays cannot amplify microbes that are not in the specimen collected; thus, false negative results can occur with some agents found in very low quantities in the bloodstream, such as *Ehrlichia canis* and feline immunodeficiency virus (FIV).

Animals that have overt microscopic evidence of infection, are culture-positive, are antigen-positive, or are positive by PCR assay for clinically relevant blood-borne pathogens should be excluded from the donor pool. Whether some pathogens that cause chronic, persistent infections can be eliminated by antimicrobial therapy is not certain, and animals with a history of previous positive test results for these pathogens should not be used as blood donors.

**Serum Antibody Tests**

Positive serum antibody assay results suggest previous infection with the pathogen in question but do not prove current infection. Negative results of antibody testing generally suggest lack of infection, but serum antibody tests may not detect early or inactive infection, or they may indicate an active infection. This situation is likely most common when the antibody test is performed during the acute stage of infection, which is well documented with several vector-borne pathogens (see *Ehrlichia* and *Anaplasma* sections). Other agents, such as *Bartonella*, are stealth organisms that evade the immune system and may not induce detectable serum antibodies. Severely immunocompromised animals also may fail to mount a specific antibody response (eg, cats with advanced FIV infection). These dogs and cats generally are ill, and hopefully would be excluded from the donor pool based on other findings.

Point-of-care assays available for detection of the antibody response to some pathogens have the advantages of being rapid and inexpensive, and the potential for operator error with most assays is small. No standardization of serological tests offered by commercial laboratories for infectious agents is available. Differences in antigen, antigen preparation, reagents, and protocols can influence the results of serological assays among laboratories and point-of-care assays. In addition, inherent subjectivity in interpretation of immunofluorescent antibody (IFA) assays can be problematic.

For some pathogens, a combination of both serological and organism demonstration techniques (cytology, culture, PCR) may be required to maximize diagnosis of infection.

**Screening of Blood Donors for Blood-borne Pathogens**

**Canine Blood-borne Pathogens**

**Dirofilaria immitis** does not meet the criteria used to categorize other vector-borne pathogens because transfusion of microfilaria from an infected donor cannot lead to heartworm disease in the recipient. However, filaremic blood transfused to a recipient has the potential to interfere with diagnostic testing, can be infectious to mosquito vectors, and can carry *Wolbachia* spp. In addition, a donor infected with *D. immitis* would not be considered a healthy donor, and collection of large amounts of blood from such a donor could be unsafe. Therefore, it is recommended that dogs and cats to be used as blood donors in heartworm endemic areas be screened for *D. immitis* infection and placed on heartworm prophylaxis.

**Anaplasma spp.** *A. phagocytophilum* and *A. platys* are the causative agents of canine granulocytic anaplasmosis and infectious canine cyclic thomboctopenia, respectively. Transmission of *A. phagocytophilum* occurs via *Ixodes scapularis* and *Ixodes pacificus* ticks in the United States. Widespread subclinical infections followed by pathogen clearance appear common in both humans and dogs. A further pathway for transmission is via infected blood, either experimentally or by blood transfusion. In human medicine, several reports of transfusion-transmission of *A. phagocytophilum* via different blood products (non-leukoreduced/leukoreduced RBCs, leukoreduced platelets) and also transfusion-transmitted granulocytic anaplasmosis have been documented. Widespread subclinical infections followed by pathogen clearance appear common in both humans and dogs, and in immunocompromised or elderly people such infections can cause severe disease. Donation screening or inactivation by pathogen reduction tech-
nologies is considered in human medicine. Anaplasmosis occurred in a splenectomized dog on chemotherapy after a packed RBC transfusion; both the donor and recipient tested positive by PCR (Kohn unpublished data). PCR positive dogs can be seronegative and can have clinical and hematologic variables within reference intervals. Antibodies to Anaplasma species can be detected using IFA assays, automated fluorescence-based systems, or point-of-care lateral flow ELISA assays. 

Serotypes cross-reactivity among Anaplasma species occurs in some assays, but not all (Table 3). The seroprevalence (IFA or ELISA) is high in endemic areas (up to 50%) and antibody titers may persist for several months or even years.

The extent to which *A. phagocytophilum* can persist in tissues and contribute to chronic disease manifestations in humans and dogs currently is unknown. In 1 study, treatment of experimentally infected dogs with prednisolone up to 6 months after infection was followed by development of positive PCR results for the organism in some dogs, thrombocytopenia, and reappearance of morulae on blood smears. In another study, dogs infected with *A. phagocytophilum* by exposure to wild-caught *Ixodes scapularis* ticks were PCR positive for at least 12 weeks. In light of the above information, the panel recommends that optimal standards are to screen donors using both serology and PCR, and dogs that test positive with 1 or both assays should be excluded. Exclusion of all seropositive dogs might limit the donor pool in endemic areas (see comments in Table 1).

*Anaplasma platys* is thought to be transmitted by *Rhipicephalus sanguineus*, and infections are common in this tick. *Anaplasma platys* can establish a chronic, persistent subclinical infection, sometimes accompanied by mild thrombocytopenia. Dogs infected experimentally with blood developed severe thrombocytopenia within 7 days after inoculation. Transfusion-transmitted infection or disease has been reported rarely in humans in North America. An IFA assay for detection of serum antibodies is commercially available, but cross-reactions occur with *A. phagocytophilum*. Species-specific PCR testing of blood samples is the diagnostic method of choice. Assays for *A. phagocytophilum* antibodies may or may not detect *A. platys* antibodies (Table 3). Donor dogs that are negative for antibodies and negative using species-specific PCR are optimal (Table 1).

**Babesia spp.** Babesiosis is caused by organisms of the genus Babesia. Babesia (*canis*) vogeli and Babesia gibsoni are the most common species diagnosed in North American dogs. Several other Babesia spp. have been identified in North America (B. canis, B. rossi, B. microti-like and un-named Babesia sp.). Transmission of Babesia spp. by transfusion is well documented in both humans and dogs. The resulting disease in dogs can be peracute, acute, chronic, or subclinical. A high seroprevalence of *B. canis* occurs in greyhounds, and an increased prevalence of *B. gibsoni* occurs in American pit bull terriers and American Staffordshire terriers, as detected by PCR. Optimal screening should include serology against *B. vogeli* and *B. gibsoni* and broad range PCR screening (ie, that which detects all known Babesia spp., that infect dogs). Minimal screening may include broad-range PCR screening only. For all “pit bull” type dogs, Greyhounds, dogs with known tick exposure or dogs with bite exposure from a “pit bull” type dog, 1 additional PCR screening should be considered beyond the optimal recommendations to enhance sensitivity.

**Bartonella spp.** Dogs can be infected by several Bartonella spp., most of which are proven or suspected to be vectored by fleas or, potentially, ticks. Bartonella vinsonii subspecies berkoffi and *B. rochalimae* were the most common species amplified from dogs and their fleas in a shelter in Florida. Bartonella henselae, which is most common in cat blood and *Ctenocephalides felis* collected from cats, also has been grown or amplified from the blood of dogs. Although *Bartonella* spp. transmission has not been documented by blood transfusion in a client-owned dog, dogs that are clinically ill dogs and positive for Bartonella spp. have been detected, healthy dogs can harbor *Bartonella* spp., and the organisms can be transmitted by inoculation. Thus, it is plausible that *Bartonella* spp. could be transmitted by blood transfusion and result in clinical illness, and the panel therefore believes testing is indicated for this genus.

An updated serological assay, PCR assay, and culture are available for both *B. henselae* and *B. vinsonii* subspecies berkoffi, and these are the most likely pathogens in dogs (Table 3). The most sensitive way to document *Bartonella* spp. in the blood of dogs is by the concurrent use of specialized culture media (Bartonella and *alpha* Proteobacteria Growth Medium [BAPGM]) and PCR assay in multiple blood samples, and this combination of tests will detect all known *Bartonella* spp. of dogs. However, BAPGM-PCR can be negative even in infected dogs if only 1 sample is tested. The panel believes the optimal standard is to use *B. henselae* and *B. vinsonii* subspecies berkoffi and BAPGM-PCR negative dogs as donors (Table 1).

In 1 canine blood donor candidate study, although 18% of screened dogs were positive for a *Bartonella* spp., only 11% were seropositive. In addition, serological cross-reactivity is variable among *Bartonella* spp., and assays are not routinely available for all species. Thus, the panel believes that *Bartonella* spp. serum antibody tests alone should not be used exclusively for assessment of dogs to be used as blood donors.

Several laboratories offer broad range PCR assays to amplify DNA of multiple *Bartonella* spp. or offer specific primers for *B. henselae* and *B. vinsonii* subspecies berkoffi (Table 3). When using *alpha* Proteobacteria Growth Medium BAPGM and BAPGM-PCR, detection of *B. henselae* and *B. vinsonii* subspecies berkoffi is not practical because of expense, turnaround time, or both, the panel believes the minimal standard is to use dogs that are PCR negative for DNA of *B. henselae* and *B. vinsonii* subspecies berkoffi.

**Ehrlichia spp.** Ehrlichia canis, *E. ewingii*, and *E. chaffeensis* are vector-borne agents belonging to the family.
Rickettsiaceae. All are capable of causing disease in dogs. Of these pathogens, *E. canis* is of greatest importance for blood donor screening because of its high prevalence worldwide and its propensity to cause chronic, persistent infections. Recent studies suggest that *E. ewingii* also is capable of causing persistent infection in dogs, but it has a more restricted geographic distribution.

**Table 3.** Laboratories offering point of care or laboratory-based assays for potential use in screening blood donors.

| Laboratory | Services |
|------------|----------|
| Abaxis | Several serological assays, including some for point-of-care |
| Animal Blood Resources International (ABRI) | Blood donor typing |
| ANTECH Diagnostics | PCR assays for some blood-borne agents |
| Biogal | Laboratory-based serological assays for some blood-borne agents |
| Specialized Infectious Diseases Laboratory Colorado State University | PCR assays for some blood-borne agents |
| Galaxy Diagnostics, Inc. | Laboratory-based serological assays for some blood-borne agents |
| IDEXX Laboratories | Combination feline *Bartonella* spp. PCR and serology |
| Michigan State University Diagnostic Center for Population and Animal Health | Laboratory-based serological assays for some blood-borne agents |
| National Veterinary Laboratories | PCR assay for *Bartonella* spp. |
| New York State Veterinary Diagnostic Laboratory/Animal Health Diagnostic Center 607-253-3900 | BAPGM culture for *Bartonella* spp. |
| North Carolina State University Vector Borne Disease Laboratory | Combination of serology, PCR, and culture for dogs or cats |
| Protatek Reference Laboratory | PCR assays for some blood-borne agents |
| Real-time PCR Research and Core Diagnostics Facility, University of California, Davis, CA | Laboratory-based serological assays for some blood-borne agents |
| Zoetis | PCR assays for some blood-borne agents |
| Zoologix | Laboratory-based serological assays for some blood-borne agents |

*The laboratories selected for inclusion either provide standard operating procedures for critical review, have published peer reviewed articles documenting quality control and assay specifics, are standard operating procedures monitored state-accredited laboratories, are laboratories producing kits licensed by the USDA, or are laboratories that panel members have worked with directly providing evidence of quality assurance. This is not meant as an exhaustive list and many other laboratories, especially state accredited laboratories, also provide quality laboratory services. Direct comparisons among different tests for infectious disease agents are generally not available unless published. See the reference list of the main document.*

Rickettsiaceae. All are capable of causing disease in dogs. Of these pathogens, *E. canis* is of greatest importance for blood donor screening because of its high prevalence worldwide and its propensity to cause chronic, persistent infections. Recent studies suggest that *E. ewingii* also is capable of causing persistent infection in dogs, but it has a more restricted geographic distribution. Experi-
mentally, SC inoculation of *E. canis* results in dose-dependent infection and positive blood cultures. Screening of potential donor dogs for antibodies to some *Ehrlichia* antigens can be performed by IFA assay, 1 of several commercial point-of-care assays or other laboratory-based assays. Variable serologic cross-reactivity occurs among some *Ehrlichia* species. In 1 of the point-of-care assays, recombinant peptide antigens of *E. canis* and *E. ewingii* are combined together in a single test. A positive result reflects the seroreactivity to *E. canis*, *E. ewingii*, or both pathogens. The sensitivity and specificity of this assay compared to IFA have been reported. The clinical sensitivity and specificity of other available assays require further study. Because serological reactivity against *E. canis*, *E. ewingii*, and *E. chaffeensis* is variable and not known for all assays, and because infection can be documented by broad-range PCR assay before seroconversion, the panel believes the optimal standard is to use donors that are seronegative and PCR negative (Table 1). This is most important for *E. canis* because it is the most important primary pathogen in these regions.

**Hemoplasmas.** Dogs can be infected with several hemoplasma species, including *Mycoplasma haemocanis*, "Candidatus *M. haemotaparvum*," and possibly also "Candidatus *M. haemominutum*" or a related organism. Although ticks have been implicated in transmission of *M. haemocanis*, the mechanism of transmission has not been proven. Kennel dogs and research animals appear to be at higher risk for infection by *M. haemocanis*. Diagnosis of infection is based on PCR assay of whole blood. No serologic assay for hemoplasma infection is commercially available. In general, dogs are subclinically infected with these organisms, but *M. haemominutum* infection in splenectomized dogs, with a few case reports of infected dogs with other immunocompromising comorbidities. Only a single clinical infection with "Candidatus *M. haemotaparvum*" has been reported in a splenectomized dog with hemic neoplasia being treated with chemotherapy. Whether or not the hemoplasmas played a role in development of anemia. This dog received several units of blood products, some of which tested positive using PCR for "Candidatus *M. haemotaparvum*" and tested negative before transfusion (Sykes et al, unpublished data). Therefore, optimally, donor dogs should be seronegative and PCR negative for all hemoplasma species. When the prevalence of hemoplasma infection in potential blood donors that are seronegative and PCR negative (Table 1). This is most important for *E. canis* because it is the most important primary pathogen in these regions.

**Hepatozoon canis** and **Hepatozoon americanum.** *Hepatozoon canis* and *Hepatozoon americanum* are tickborne protozoal pathogens that are transmitted primarily by ingestion of *Rhipicephalus sanguineus* or *Amblyomma maculatum* ticks, respectively. In North America, the distribution of these infections primarily is limited to the south-central and south-eastern United States, with occasional *H. americanum* infections identified in other states, including Washington, Vermont, California, and Nebraska. Most *H. canis* infections are subclinical, and *H. americanum* can cause lethargy, fever, locomotory abnormalities, hyperesthesia, and protein-losing nephropathy. The organisms circulate in the peripheral blood as gamonts in leukocytes. There are no reports of transmission by blood transfusion. Screening could be considered in endemic areas using specific PCR assay for *H. canis* or *H. americanum*. Serologic assays for routine diagnostic purposes are not available in North America.

**Leishmania spp.** Leishmaniosis is caused by protozoan organisms of the genus *Leishmania* and is transmitted to dogs in Mediterranean regions by the bite of an infected female sandfly. The vector in North America is not known; *Lutzomyia shannoni* is the most highly suspected vector in the United States, but dog-to-dog transmission also has been hypothesized. Visceral leishmaniosis, caused by *Leishmania donovani*, is considered an exotic disease in dogs in North America, with the exception of the populations in endemic countries months to years before diagnosis. Visceral leishmaniosis has been transmitted by blood transfusion to dogs, with clinically healthy foxhounds as blood donors. A retrospective analysis of 2,200 dogs performed on 12,000 serum samples from foxhounds and other canids in the United States reported an 8.9% seroprevalence in foxhounds, but no other randomly selected domestic dogs or wild canids were seropositive. Because the infection appears to be only endemic in foxhounds in North America, screening of every potential blood donor is not necessary. However, all foxhounds and dogs with travel history to or from endemic countries should be screened for *Leishmania* spp infection using IFA serology performed by a reputable laboratory. Because IFA serology may lack sensitivity in subclinically infected dogs, foxhounds or dogs living in or traveling to endemic areas, and found to be seronegative should then be screened additionally by *Leishmania* PCR. The IFA assay for *Leishmania* spp. can cross-react with *Trypanosoma cruzi*. Although dogs with either infection should be excluded as blood donors, *Leishmania* spp. seropositive dogs can be evaluated for the presence of both pathogens with the PCR assay for *T. cruzi* if further clinical information is desired.

**Neorickettsia risticii.** Dogs can be experimentally infected with *N. risticii*, and antibodies to *N. risticii* have been detected in pet dogs. Polymerase chain reaction was used in 1 study to identify *N. risticii* obtained from blood cultures of 2 clinically ill dogs. There is no documentation of transmission of *N. risticii*
to dogs by blood transfusion. Although the committee believes that optimally dogs should test PCR-negative for Neorickettsia risticii infections, no screening is also acceptable.

**Rickettsia felis.** Rickettsia felis is a member of the spotted fever group rickettsiae in dogs in the United States. These agents are likely to induce serological cross-reactivity in the *R. rickettsii* assay. It is currently assumed that these agents are not associated with illness in dogs but further study is needed. There is evidence that dogs are the reservoir for *R. felis*49 and *Ctenocephalides felis* collected from cats in the United States are commonly positive for *R. felis* DNA.50 It is currently unknown whether transfusion of a large volume of blood from a *R. felis* carrier dog to an ill dog in need of a transfusion would have clinical sequelae. A PCR assay is the only way currently to prove *R. felis* infection in dogs. Although the panel believes that optimally dogs should test PCR-negative for *R. felis* infections, no screening is also acceptable (Table 1).

**Trypanosoma cruzi.** American trypanosomiasis (Chagas disease) is caused by *Trypanosoma cruzi*, a hemoflagellate protozoan. Transmission most commonly occurs through a feces-contaminated bite from, or ingestion of, triatomine bug vectors. A small number of transfusion-acquired *T. cruzi* infections have been reported in people in North America. All patients were immunocompromised at the time of infection, and 2 of 3 dogs were positive by PCR. *T. cruzi* is endemic (South and Central America).52 In 2010, the Food and Drug Administration recommended that all presenting human blood donors be asked about a history of Chagas disease in addition to being tested at least once using a licensed screening test.53,54 Infection in dogs can result in acute or chronic myocarditis, but in 1 study, dogs that were experimentally inoculated with *T. cruzi* were parasitemic but only developed transient lymphadenopathy. Survivors of acute disease can remain subclinically infected for several months until chronic myocarditis develops. Infection is characterized by detectable concentrations of specific antibodies and low concentrations of circulating parasites.56

Most dogs that develop trypanosomiasis in the United States reside in Texas or in the southwestern states. The seroprevalence in a 2014 study of 205 dogs from 7 shelters in diverse ecoregions in Texas was 8.9%.57 Transmission to dogs by blood transfusion has not been reported. Dogs with a history of travel to and from endemic areas (Texas, New Mexico, Arizona, southern California, Mexico, Central America and South America) should be considered for serological screening by IFA, indirect hemagglutination assays (IHA), ELISA, or immunochromatographic dipstick tests, and seropositive donors should be excluded from the donor pool. Serologic cross-reactions between *T. cruzi* and *Leishmania* spp. have been documented.58 A PCR assay to detect *T. cruzi* in whole blood also could be considered.59

**Non Vector-borne Pathogens—Testing Recommended**

**Brucella canis.** Brucella canis, a zoonotic pathogen, is a gram-negative bacterium that causes brucellosis in dogs. Venereal transmission can occur during breeding, or transmission can follow oronasal contact with vaginal discharges, aborted material, and urine from infected dogs. In humans, only a few transfusion-transmitted *Brucella* infections have been documented worldwide.60–62 Transmission of *B. canis* by blood transfusion has not been documented in dogs. However, infection is associated with prolonged bacteremia that may be subclinical, and thus the potential for transmission by transfusion exists.63

Because it is commercially available and results can be obtained in minutes, serological screening of potential donors for antibodies using the rapid slide agglutination test (RSAT) initially is recommended.6 Positive dogs should be excluded as blood donors. In addition confirmatory diagnostic assays performed using blood culture, PCR on whole blood, tube agglutination tests, agarose gel immunodiffusion tests, or ELISA tests. A single negative RSAT is sufficient for neutered donors to meet optimal standards, but RSAT screening should be repeated in sexually active intact dogs. This approach is supported by numerous studies that have concluded that RSAT is highly sensitive, but lacks specificity.64 In recent studies, PCR assays performed on whole blood or genitourinary secretions were found to be more sensitive than serologic tests, notably in the early phase of infection.65–69

**Other Pathogens—Testing Not Recommended**

**Borrelia burgdorferi.** Lyme borreliosis is caused by the spirochete *Borrelia burgdorferi*, which is vectored by *Ixodes* spp.70 Many dogs in the northeastern and upper Midwest regions of the United States are seropositive, and a small percentage of dogs develop polyarthritis or nephritis.71 Transfusion-related infections have not been reported. Despite the ability to culture *B. burgdorferi* from human blood,72 studies in humans have demonstrated that the risk of acquiring Lyme disease from a transfused unit of packed red blood cells or platelets is negligible.73,74 In a study in dogs, only 1.6% of 576 blood samples from experimentally infected dogs tested positive for *B. burgdorferi* by PCR.75 The consensus of the panel is that healthy canine blood donors should not be screened for *B. burgdorferi*. If a screening test that detects seroreactivity to other pathogens is used and the donor is seropositive to *B. burgdorferi*, that animal need not be excluded from the donor pool.

**Neorickettsia helminthoeca.** Testing of blood donor dogs for *N. helminthoeca* is not recommended because the pathogen produces acute disease, without evidence of a carrier state in healthy dogs and without evidence of blood-borne transmission.76

**Rickettsia rickettsii.** Rocky mountain spotted fever (RMSF), caused by *Rickettsia rickettsii*, is an acute systemic infection of vascular endothelial cells. The organism is rapidly eliminated from dogs that survive clinical...
illness, and chronic carrier states have not been reported. The consensus of the panel is that healthy blood donors do not need to be screened for antibodies to R. rickettsii, because infected dogs are acutely ill and no subclinical carrier state is known to exist. Dogs that are seropositive for *Rickettsia* spp. need not be excluded as blood donors.

**West Nile virus.** West Nile virus (WNV) is a mosquito-borne zoonotic arbovirus (genus Flavivirus). Most infected humans are asymptomatic or have mild disease characterized by fever, headache, muscle ache, and skin rash; meningoencephalitis develops in <1% of cases. Although dogs can become viremic after infection with WNV, they typically develop a subclinical viremia of low magnitude followed by clearance of the virus. Only rarely has West Nile viremia been documented in cats, but PCR-positive sera have been identified in a small percentage of blood donor cats from endemic areas in the United States. 

Because infection of blood donors does not need to be tested for WNV,

**Feline Pathogens**

**Vector-borne Pathogens—Testing Recommended**

**Anaplasma spp.** Cats with *A. phagocytophilum* infections can develop mild clinical illness that resolves quickly with administration of doxycycline. Research cats infected with field-caught *I. scapularis* from endemic areas become PCR positive before seroconversion, develop antibodies that can be detected by a commercially available assay used with dog sera, and maintain rickettsemia for weeks before administration of doxycycline. In addition, some cats with *A. phagocytophilum* infections will have morulae visualized cytologically in the cytoplasm of neutrophils. Because this organism causes illness in cats, can be transmitted experimentally by blood inoculation, results in persistent infection, and is associated with illness, the panel recommends that optima-ly healthy cats from endemic areas be screened for *A. phagocytophilum* infection by serology and PCR and be negative in both tests (Table 2). However, in endemic areas, seropositive cats may be common, limiting the blood donor pool. Thus, the committee believes that if blood donor cats that are *A. phagocytophilum* seronegative and PCR negative are not available, cats that are *A. phagocytophilum* seropositive but PCR (or culture) negative could be used (Table 2). Because infection of cats with *A. platys* occasionally has been documented, cats living in areas endemic to *Rhipecephalus* spp. ticks should be screened with PCR (Table 2).

**Bartonella spp.** A number of *Bartonella* spp. have been grown or amplified from the blood of cats, most commonly *B. henselae*, *B. claridgeiae*, *B. koehleriae*, and *B. quintana*. Cats are the reservoirs and *Coxiella burnetii* is the vector for *B. henselae*, *B. claridgeiae*, and *B. koehleriae*; these agents are extremely common in the blood of cats and their fleas. *Bartonella henselae* infection was only documented by PCR assay in 2 of 117 (1.7%) community source cats used as blood donors in the United States, which likely reflects the use of flea control products. Infected cats typically have a prolonged, subclinical bacteremia, but a number of clinical sequelae also occur. *Bartonella* spp. can be transmitted by blood transfusion, and storing blood does not inactivate the organism.

The most sensitive way to document *Bartonella* spp. in the blood of cats is by the concurrent use of specialized culture media and PCR assay using several blood samples. Although this approach frequently is needed to prove the presence of *Bartonella* spp. in the blood of clinically ill dogs, whether the increased sensitivity needed for screening cats to be used as blood donors remains to be proven. Because cats are the definitive host for *B. henselae*, high levels of bacteremia often are detected even when the cats are healthy. Thus, broad range PCR assays or PCR assays using specific primers that are used widely in commercial laboratories in the United States are likely to detect most infected cats (Table 3). Bacteremia in cats infected with *B. henselae* by exposure to infected *C. felis* precedes seroconversion by 7–42 days and thus serology alone is inadequate as a screening test. However, after immune responses develop, bacteremia is intermittent and a false negative result could occur only if a single sample is assayed. Thus, the panel recommends as the optimal standard to use cats that are seronegative and PCR assay or culture negative (Table 2).

Because the majority of states in the United States are endemic for *C. felis*, *Bartonella* spp. seroprevalence rates can be as high as 93%. The committee recognizes the minimal standard is to use a *Bartonella* spp. PCR negative cat (Table 2). Use of antibiotics does not consistently eliminate *Bartonella* spp. infections in cats, and thus PCR or culture positive cats should be excluded from the blood donor program.

**Cyttauxzoon felis.** *Cyttauxzoon felis* is a tickborne protozoan pathogen in the order Piroplasmida and family Theileriidae. In this section, *Cyttauxzoonosis* is used to denote the acute illness (ie, systemic inflammatory response syndrome, cytopenias, multi-organ failure) associated with *C. felis* infection. After tick transmission, the organism undergoes schizogony in myeloid cells (specific lineage is unknown) followed by merozoitary in erythrocytes. The schizogenous stage is associated with illness and disease can be transmitted experimentally by transmission of blood from a cat with *Cyttauxzoonosis* to a naive cat. The majority of cats with *Cyttauxzoonosis* that are presented to veterinary hospitals develop severe febrile illness, cytopenias, and often die within 5 days of presentation if appropriate treatments are not given. A carrier state (erythrocyte infection only) has been identified that is not associated with clinical disease. In fact, transfusion of blood from a chronically infected cat into a naive cat does not result in illness. A theoretical risk for transmission of *Cyttauxzoonosis* exists because parasitemia can precede
illness. In experimental infection, parasite DNA can be detected as early as 7 days post-infection but clinical signs do not begin until 10–21 days post-infection. Serological assays are not available. Use of indoor only cats receiving appropriate ectoparasite prophylaxis is advised to avoid this disease in donor animals. Appropriate donor selection and pre-donation physical examinations should minimize transmission risk. The panel recommends as the optimal standard to use PCR negative cats as donors (Table 2).

**Ehrlichia canis**. Client-owned cats with clinical signs of disease have been documented with *E. canis* results.82,83,92 Thus, although the committee believes that healthy cats in the United States have yielded negative *E. canis* results,44,95 By contrast, in North America, *E. canis* is rarely (<1%) detected in non-anemic client-owned pet cats that are either apparently healthy or brought to veterinary clinics for reasons other than anemia.83,93–95 Although febrile cats have been suggested to be involved in transmission, the evidence for flea-borne transmission is weak. Epidemicologic evidence suggests that aggressive interactions between cats may lead to transmission.95 Invasive inoculation of infected blood has been used to produce experimental infections.97 No serologic assay for infection is commercially available. Blood smear evaluation is insensitive (especially for chronic carrier cats) and also lacks specificity (organisms can easily be confused with stain precipitate or drying artifacts), and thus the diagnostic test of choice for screening blood donors is PCR. Because of the pathogenicity of *M. haemofelis*, the panel agreed that all cats should be tested for *M. haemofelis* and those that test positive should be excluded from the blood donor pool. Optimal cats should be tested for “Candidatus M. haemominutum” and “Candidatus M. turicensis” and excluded from the donor pool, but given the high prevalence of these organisms in the cat population and the lack of compelling evidence that they are associated with disease even in immunosuppressed cats, the panel agreed that screening for these pathogens could be considered optional and positive cats could be used as donors in the absence of a source of negative blood (Table 2). Because antimicrobial therapy does not reliably eliminate hemoplasmas (and appears particularly ineffective for treatment of “Candidatus M. haemominutum” infections), the panel does not recommend treating potential donors with antimicrobials in an attempt to eliminate infection.

Importantly, *M. haemofelis* appears to be inactivated during storage of whole blood for 1 week.98 “Candidatus M. haemominutum” may remain viable in blood products for ≥1 week, although inactivation appears to occur after 1 month of storage.

**Neorickettsia risticii** can infect cats after experimental inoculation but has not been detected in naturally exposed cats.99 Although the committee believes that optimally cats should test PCR-negative for *Neorickettsia risticii* infections, no screening also is acceptable (Table 2).

## Non Vector-borne Pathogens—Testing Recommended

**Feline Leukemia Virus**. Transmission of Feline Leukemia Virus (FeLV) occurs primarily through saliva, but the virus is present in the blood and can be transmitted by blood transfusion.100 Screening of donor cats for FeLV using an ELISA that detects soluble circulating core viral antigen p27 in the peripheral blood is recommended, and all cats testing antigen-positive should be excluded as blood donors. With the recognition that cats exposed to FeLV can develop regressive infection (defined as transient or undetectable antigenemia with proviral DNA in the blood), optimally real-time PCR testing for proviral DNA should be performed, because FeLV provirus is infectious.101,102 However, PCR assays for FeLV proviral DNA currently available in the United States have not been evaluated for clinical sensitivity and specificity. Regressor cats have detectable proviral DNA and viral RNA in many tissues, including the bone marrow, many years after FeLV exposure, indicating that these cats do not completely clear the virus.103 Regressor cats can transmit FeLV infection to recipient cats through blood transfusions, and the recipients can then go on to develop progressive infection.6 Furthermore, reactivation of FeLV infection in regressor cats with and without immune suppression has been reported.103 Reactivation of a regressive FeLV infection has the potential to place FeLV-negative donor cats at risk if housed together in a colony situation if reactivation occurs in the interval between routine screening tests (eg, annual screening) and is not detected. Free-roaming cats have constant potential exposure and should be excluded from blood donor programs.

**Feline Immunodeficiency Virus**. Feline Immunodeficiency Virus (FIV) is transmitted primarily through bite wounds, but it can be readily transmitted via inoculation of infected blood.104,105 Testing of donor cats for FIV-specific antibodies by ELISA (which uses immobilized FIV core proteins p2492g and p15 to capture antibodies in blood) is recommended, and all seropositive cats should be excluded from the donor pool. Cats vaccinated against FIV also will be seropositive. Definitive differentiation of infected from vaccinated cats is challenging, because virus isolation, the gold standard for diagnosis of FIV infection, is time-consuming and expensive. Real-time quantitative PCR assays for FIV are moderately sensitive...
and highly specific for FIV infection, but positive results have occurred in uninfected, vaccinated cats. Therefore, until reliable approaches are available that conclusively discriminate naturally infected cats from vaccinated cats, the panel recommends that all seropositive cats, including vaccinated cats, be excluded from the donor pool. Free-roaming cats also should be excluded from donor programs.

Other Pathogens—Testing Not Recommended

**Feline Coronavirus.** Although cats can be subclinically infected with feline coronavirus, documentation of transmission of the virus by blood transfusion does not exist at this time. Screening of blood donor cats with serology or reverse transcriptase (RT)-PCR is not recommended, because healthy cats can have antibody titers against feline coronavirus and also can be RT-PCR positive. The consensus of the panel was not to screen for coronavirus antibodies or RNA in clinically healthy cats being considered as blood donors.

**Rickettsia felis.** The dog has recently been documented to be the reservoir for this agent, and studies have failed to amplify *R. felis* DNA from the blood of cats. Thus, the panel does not recommend screening for this organism in cats.

**Toxoplasmosis.** Cats are the definitive host for *Toxoplasma gondii*, an intracellular coccidian parasite. Although *Toxoplasma gondii* antigens and DNA have been detected in healthy cats by PCR assay, transmission by blood transfusion has not been documented. For purposes of blood safety, the consensus of the panel is that there is no indication for screening healthy potential donor cats for *T. gondii* antigens, antibodies, or DNA.

**General Recommendations**

Tables 1 and 2 present current recommendations for blood donor screening. The consensus panel hopes that its findings will lead to reevaluation of the current infectious disease screening process for potential canine and feline donors. Diagnostic laboratories should reexamine their donor screening panels, offering assays for those pathogens that are of most concern in blood-borne disease transmission.

**Management Techniques**

The panel agreed on several management techniques designed to decrease the risk of disease transmission by blood transfusion.

**Donor Selection and Care**

1. Standardized forms (Tables 4–7) should be completed at enrollment of potential blood donors and before each donation.
2. A complete history and thorough physical examination, including determination of rectal temperature of the donor animal, should be completed before each blood collection.
3. Use of antimicrobial drugs to prevent or treat possible infection is not acceptable as a substitute for laboratory testing of potential blood donors.
4. Initial clinicopathologic screening of potential donors is advised (eg, CBC, serum biochemistry, urinalysis, fecal examination). Determination of the PCV is advised before each collection.

**Blood Collection Procedure Recommendations**

1. All blood for transfusion should be collected in an aseptic manner.
2. Before administration, the label of the blood product should be examined for the following: collection and expiration dates, donor species, product type, and blood type.
3. Before administration, blood products should be visually inspected. Bacterial contamination should be suspected if bag segments appear much lighter in color than the bag itself, the red blood cell mass appears purple, a zone of hemolysis is observed just above the red cell mass, clots are visible, or the plasma or supernatant fluid is murky, purple, brown, or red. In the presence of any of these findings, culture of the blood should be performed to determine whether contamination has occurred. If the unit appears abnormal, it should not be administered.
4. Currently, screening of individual units for infectious disease is not practical in veterinary medicine because of the turnaround time and costs of testing. However, this model should be considered the gold standard.
5. An aliquot of plasma and whole blood tube segments from each donated unit of blood should be stored. This practice allows retrospective testing in cases of suspected transfusion-associated disease transmission.

**Records**

1. Records should be kept on all transfusions, documenting both the donor unit used and the recipient of the transfusion. Appropriate records must be kept so that all recipients receiving blood from a given donor can be easily contacted should that donor be found to carry an infectious disease agent.
2. Development of consent forms detailing potential disease transmission risks should be considered for owners of patients receiving transfusions.

**Summary**

Thousands of blood transfusions are performed each year on dogs and cats, and the demand for blood products continues to grow. Risks associated with transfusions include the risk of disease transmission. Appropriate screening of blood donors for blood-borne infectious disease agents should be performed to decrease this risk. Geographic restrictions
Table 4. Potential canine blood donor evaluation form.

### Owner Information

| Field                                      | Details                           |
|--------------------------------------------|-----------------------------------|
| Owner Name                                 |                                   |
| Home Address                               |                                   |
| City / State / Zip                         |                                   |
| Home Telephone                             |                                   |
| Alternate Phone                            |                                   |
| E-mail address                             |                                   |

### Donor Information

| Field                                      | Details                           |
|--------------------------------------------|-----------------------------------|
| Pet’s Name                                 | Breed(s):                         |
| Sex: M F Spayed/Neutered: Y N Age          |                                   |
| Approximate date of birth                  | Current Weight:                   |
| How old was your dog when you obtained him/her? |                     |
| Approximate dates of last vaccinations:    | Distemper/Parvo: Corona: Rabies: Other: |
| Is your dog currently on:                  | Heartworm preventative? Y N Approx. date of last heartworm test? |
|                                            | Tick/ flea preventative? Y N Describe: |
| Has your dog had any health problems, even minor ones – in the past or currently? |请描述: |

### Additional Information—To be completed by attending clinician or transfusion technician only

| Field                                      | Details                           |
|--------------------------------------------|-----------------------------------|
| Does the dog meet weight requirements? Y N |                                   |
| Does the dog have a readily accessible jugular vein? Y N Comment: | Comment: |
| Is the dog friendly and easy to handle? Y N |                                   |
| Do you think the dog would lie still for 10 minutes during donation? Y N |                                   |
| Do you see any problems that would prevent this dog from being a blood donor? Y N |                                   |
| Comments:                                  |                                   |

| Field                                      | Details                           |
|--------------------------------------------|-----------------------------------|
| Signature Date                             |                                   |
| DEA results/assay/date Date owner notified |                                   |
| Infectious agents screening performed/cleared? Y N Date owner notified |                                   |
Table 5. Potential feline blood donor evaluation form.

| Owner Information |
|--------------------|
| Owner Name:        |
| Home Address:      |
| City / State / Zip:|
| Home Telephone:    |
| Alternate Phone:   |
| E-mail address:    |

| Donor Information |
|-------------------|
| Pet’s Name:        |
| Breed(s):          |
| Sex: M F           |
| Spayed/Neutered: Y N |
| Age:               |
| Approximate date of birth: |
| Current Weight:    |

| How old was your cat when you obtained him/her? |
|------------------------------------------------|
| Approximate dates of last vaccinations: |
| Herpes/Calici/Parvovirus vaccines: |
| FeLV: |
| Rabies: |
| Other: |

| Is your cat currently on: |
| Heartworm preventative? Y N |
| Approx. date of last heartworm test: |
| Ticks/flea preventative? Y N |
| Describe: |

| Has your cat had any health problems, even minor ones – in the past or currently? Y N |
| Please describe: |

| Does your cat have outdoors access? |
|-------------------------------------|

| Is your cat on any medications (NSAIDs, aspirin, vitamins, herbals, etc.)? |

| Has your cat ever received a blood or plasma transfusion? |

| Has your cat ever been pregnant? |

| Do you travel with your cat? Y N |
| If yes, where? |

| Are you comfortable with a 2” area of hair to be clipped from your cat’s neck? Y N |

| Clipping is a necessary procedure to aseptically prepare the area for venipuncture. |

| Are you comfortable with sedation and/or anesthesia of your cat? Y N |

| This is a necessary procedure prior to blood collection in donor cats. |

| Additional Information—To be completed by attending clinician or transfusion technician only |

| Does the cat meet weight requirements? Y N |

| Does the cat have a readily accessible jugular vein? Y N Comment: |

| Is the cat friendly and easy to handle? Y N Comment: |

| Do you see any problems that would prevent this cat from being a blood donor? Y N Comments: |

| Signature Date: |
|-----------------|

| Blood type results/assay/date Date owner notified: |

| Infectious agents screening performed/cleared? Y N Date owner notified: |
### Table 6. Pre-donation history questionnaire for canine blood donors.

#### Donor Information

| Pet’s Name: | Owner Name: | Sex: M F Spayed/Neutered: Y N Age | Current Weight: | Date of last donation: | Jugular used? L R |
|------------|-------------|----------------------------------|----------------|------------------------|-------------------|

#### Is your dog

1. Acting healthy and well today? [ ] [ ]
2. Receiving heartworm preventative? [ ] [ ]
3. Receiving tick/flea preventative? [ ] [ ]
4. Taking any medications other than heartworm and flea/tick preventatives? [ ] [ ]

#### In the 48 hours following your dog’s last blood donation

5. Was your dog’s activity level normal? [ ] [ ]
6. Did your dog experience any gastrointestinal signs (diarrhea, vomiting, lack of appetite)? [ ] [ ]

#### Since your dog’s last blood donation

7. Has your dog had any health problems, even minor ones? [ ] [ ]
8. Have you noticed any fleas or ticks on your dog? [ ] [ ]
9. Have you travelled with your dog? [ ] [ ]
10. Has your dog received a blood or plasma transfusion? [ ] [ ]
11. Has your dog been involved in any fights/bites? [ ] [ ]
12. Has your dog been sexually active? [ ] [ ]
13. Has your dog been (or is) pregnant? [ ] [ ]
14. Has your dog been on a raw diet? [ ] [ ]
15. Are you comfortable with a 3” area of hair being clipped from your dog’s neck? [ ] [ ]

#### Additional Information—To be completed by attending clinician or transfusion technician only

Rectal temperature: ____________________________
Pre-donation PCV/TS: ____________________________

Do you see any problems that would prevent this dog from donating today? Y N
Comments: __________________________________________

Was the blood donation uneventful? Y N
Comments: __________________________________________

Signature ____________________________ Date ____________________________
Table 7. Pre-donation history questionnaire for feline blood donors.

**Donor Information**

| Pet’s Name: | ___________________________ | Owner Name: | ___________________________ |
| Sex: | M | F | Spayed/Neutered: | Y | N | Age ___________________________ |
| Current Weight: | ___________________________ |
| Date of last donation: | ___________________________ | Jugular used? | L | R |

| Is your cat | | |
| 1. Acting healthy and well today? | ☐ | ☐ |
| 2. Receiving heartworm preventative? | ☐ | ☐ |
| 3. Receiving tick/flea preventative? | ☐ | ☐ |
| 4. Taking any medications other than heartworm and flea/tick preventatives? | ☐ | ☐ |

| In the 48 hours following your cat’s last blood donation | | |
| 5. Was your cat’s activity level normal? | ☐ | ☐ |
| 6. Did your cat experience any gastrointestinal signs (diarrhea, vomiting, lack of appetite)? | ☐ | ☐ |

| Since your cat’s last blood donation | | |
| 7. Has your cat had any health problems, even minor ones? | ☐ | ☐ |
| 8. Have you noticed any fleas or ticks on your cat? | ☐ | ☐ |
| 9. Has your cat been outside your house? | ☐ | ☐ |
| 10. Have you travelled with your cat? | ☐ | ☐ |
| 11. Has your cat received a blood or plasma transfusion? | ☐ | ☐ |
| 12. Has your cat been involved in any fights/bites? | ☐ | ☐ |
| 13. Has your cat been (or is) pregnant? | ☐ | ☐ |
| 14. Are you comfortable with a 2” area of hair being clipped from your cat’s neck? | ☐ | ☐ |
| 15. Your cat will be sedated and/or anesthetized before the blood collection. Have the risks associated with this been previously explained to you? | ☐ | ☐ |

**Additional Information—To be completed by attending clinician or transfusion technician only**

| Rectal temperature: | ___________________________ |
| Pre-donation PCV/TS: | ___________________________ |
| Do you see any problems that would prevent this cat from donating today? | Y | N |
| Comments: | ___________________________ |
| Sedation used (drugs, dosage, route of administration): | ___________________________ |
| Was the blood donation uneventful? | Y | N |
| Comments: | ___________________________ |
| Signature | ___________________________ | Date | ___________________________ |
of disease, breed predilection, and documentation of actual disease transmission by transfusion all are factors that might need to be considered when making a decision on what screening program to use. In addition, factors involving general health care and management of blood donors should be employed to further ensure blood safety.

Footnotes

a Canine SNAP 4DX Plus Test, IDEXX Laboratories Inc, Westbrook, ME
b Accuplex4 BioCD system, Antech Diagnostics, Lake Success, NY
c WITNESS®Ehrlichia, Zoetis, Florham Park, NJ
d Immunocomb Canine Ehrlichia Kit®, BIOGAL, Galed Labs, Aes Ldt, Israel
e D-TEC® CB Canine Brucellosis Antibody Test Kit, Zoetis, Florham Park, NJ
f Bradbury CA, Green M, Brewer M, et al Survival of Bartonella henselae in the blood of cats used for transfusion. Proceedings of the American College of Veterinary Internal Medicine Forum (abstract), Anaheim, CA, June 11, 2010 (poster).
g Hofmann-Lehmann R. Feline Leukemia Virus Infection: Where Do We Stand? Proceedings of the Second International Society for Companion Animal Infectious Diseases Symposium, San Francisco, CA, 2012.

Acknowledgments

Conflict of Interest Declaration: Dr. Lappin has been a paid consultant and researcher for IDEXX and Antech Diagnostics. Dr. Sykes has been a paid consultant for UC Davis Tagman Laboratory and IDEXX. Dr. Sykes has received research grants from UC Davis Center for Companion Animal Health.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References

1. Maggi RG, Birkenheuer AJ, Hegarty BC, et al. Comparison of serological and molecular panels for diagnosis of vector-borne diseases in dogs. Parasit Vectors 2014;7:127.
2. Dingman P, Levy JK, Kramer LH, et al. Association of Wolbachia with heartworm disease in cats and dogs. Vet Parasitol 2010;170:50–60.
3. Egenvall A, Bjöersdorff A, Lilliehook I, et al. Early manifestations of granulocytic ehrlichiosis in dogs inoculated experimentally with a Swedish Ehrlichia species isolate. Vet Rec 1998;143:412–417.
4. Centers for Disease Control and Prevention. Anaplasma phagocytophilum transmitted through blood transfusion – Minnesota, 2007. MMWR Mortal Wkly Rep 2008;57:1145–1148.
5. Townsend RL, Moritz ED, Fialkow LB, et al. Probable transfusion-transmission of Anaplasma phagocytophilum by leukoreduced platelets. Transfusion 2014;54:2828–2832.
6. Kohn B, Sillaghi C, Galke D, et al. Infections with Anaplasma phagocytophilum in dogs. Res Vet Sci 2011;91:71–76.
7. Moroff S, Sokolchik I, Woodring T, et al. Detection of antibodies against Anaplasma phagocytophilum in dogs using an automated fluorescence based system. Vet J 2014;202:348–352.
8. Stillman BA, Monn M, Liu J, et al. Performance of a commercially available in-clinic ELISA for detection of antibodies against Anaplasma phagocytophilum, Anaplasma platsy, Borrelia burgdorferi, Ehrlichia canis, and Ehrlichia ewingii and Dirofilaria immitis antigen in dogs. J Am Vet Med Assoc 2014;245:80–86.
9. Bowman D, Little SE, Lorentzen L, et al. Prevalence and geographic distribution of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: Results of a national clinic-based serology survey. Vet Parasitol 2009;160:138–148.
10. Egenvall A, Lilliehook I, Bjöersdorff A, et al. Detection of granulocytic Ehrlichia species DNA by PCR in persistently infected dogs. Vet Rec 2000;146:186–190.
11. Harvey JW. Anaplasma platys infection (thrombocytotropic anaplasmosis). In: Greene CE, ed. Infectious Diseases of the Dog and Cat, 4th ed. St. Louis, MO: Elsevier; 2012:256–259.
12. Gaunt SD, Beall MJ, Stillman BA, et al. Experimental infection and co-infection of dogs with Anaplasma platys and Ehrlichia canis: Hematologic, serologic and molecular findings. Parasit Vectors 2010;3:33.
13. Santos AS, Alexandre N, Sousa R, et al. Serological and molecular survey of Anaplasma species infection in dogs with suspected tick-borne disease in Portugal. Vet Rec 2009;164:168–171.
14. Herwaldt BL, Neitzel DF, Gorlin JB. Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6 month period. Transfusion 2002;42:1154–1158.
15. Dobroszycki J, Herwaldt BL, Doctor F. A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. J Am Med Assoc 1999;281:927–930.
16. Freeman MJ, Kirby BM, Panciera DL, et al. Hypotensive shock syndrome associated with acute Babesia canis infection in a dog. J Am Vet Med Assoc 1994;204:94–96.
17. Stegeman JR, Birkenheuer AJ, Kruger JM, Breitschwerdt EB. Transfusion-associated Babesia gibsoni infection in a dog. J Am Vet Med Assoc 2003;222:959–963.
18. Taboada J, Harvey JW, Levy MG, Breitschwerdt EB. Sero-prevalence of babesiosis in Greyhounds in Florida. J Am Vet Med Assoc 1992;200:47–50.
19. Macintire DK, Boudreaux MK, West GD, et al. Babesia gibsoni infection among dogs in the southeastern United States. J Am Vet Med Assoc 2002;220:325–329.
20. Birkenheuer AJ, Levy MG, Stebbins M, et al. Serosurvey of anti-Babesia antibodies in stray dogs and American Pit Bull Terriers and American Staffordshire Terriers from North Carolina. J Am Anim Hosp Assoc 2003;39:551–557.
21. Breitschwerdt EB, Maggi RG, Chomel BB, Lappin MR. Bartonellosis: An emerging infectious disease of zoonotic importance to animals and human beings. J Vet Emerg Crit Care (San Antonio) 2010;20:8–30.
22. Yore K, DiGangi B, Brewer M, et al. Flea species infesting dogs in Florida and Bartonella spp. prevalence rates. Vet Parasitol 2014;199:225–229.
23. Cherry NA, Diniz PP, Maggi RG, et al. Isolation or molecular detection of Bartonella henselae and Bartonella vinsonii subsp. berkoffii from dogs with idiopathic cavitary effusions. J Vet Intern Med 2009;23:186–189.
24. Pappalardo BL, Brown TT, Tompkins M, Breitschwerdt EB. Immunopathology of Bartonella vinsonii (berkoffii) in experimentally infected dogs. Vet Immunol Immunopathol 2001;83:125–147.
25. Duncan AW, Maggi RG, Breitschwerdt EB. A combined approach for the enhanced detection and isolation of Bartonella species in dog blood samples: Pre-enrichment liquid culture fol-
lowed by PCR and subculture onto agar plates. J Microbiol Methods 2007;69:273–281.

26. Balakrishnan N, Musulin S, Varanat M, et al. Serological and molecular prevalence of selected canine vector borne pathogens in blood donor candidates, clinically healthy volunteers, and stray dogs in North Carolina. Parasit Vectors 2014;7:116–124.

27. Starkey LA, Barrett AW, Beall MJ, et al. Persistent *Ehrlichia ewingii* infection in dogs after natural tick infestation. J Vet Intern Med 2015;29:552–555.

28. Gaunt SD, Corstvet RE, Berry CM, Brennan B. Isolation of *Ehrlichia canis* from dogs following subcutaneous inoculation. J Clin Microbiol 1996;34:1429–1432.

29. Obara H, Fujihara M, Watanabe Y, et al. A feline hemoplasma, “Candidatus Mycoplasma haemominutum”, detected in dog in Japan. J Vet Med Sci 2011;73:841–843.

30. Valle SF, Messick JB, Dos Santos AP, et al. Identification, occurrence and clinical findings of canine hemoplasmas in southern Brazil. Comp Immunol Microbiol Infect Dis 2014;37:259–265.

31. Willi B, Novacco M, Meli M, et al. Haemotropic mycoplasmas of cats and dogs: Transmission, diagnosis, prevalence and importance in Europe. Schweiz Arch Tierheilkd 2015;157:237–244.

32. Brinsson J, Messick J. Use of a polymerase chain reaction assay for detection of *Haemobartonella canis* in a dog. J Am Vet Med Assoc 2001;218:1943–1945.

33. Sykes JE, Baliff NL, Ball LM, et al. Identification of a novel hemotropic mycoplasma in a splenectomized dog with hemic neoplasia. J Am Vet Med Assoc 2004;224:1946–1951.

34. Compton SM, Maggi RG, Breitschwerdt EB. Candidatus Mycoplasma haematoapurvum and Mycoplasma haemacisin infections in dogs from the United States. Comp Immunol Microbiol Infect Dis 2012;35:577–582.

35. Allen KE, Johnson EM, Little SE. Hepatozoon spp infection in the United States. Vet Clin North Am Small Anim Pract 2011;41:1221–1238.

36. Li Y, Wang C, Allen KE, et al. Diagnosis of canine Hepatozoon spp. infection by quantitative PCR. Vet Parasitol 2008;157:50–58.

37. Maroli M, Gradoni L, Oliva G, et al. Guidelines for prevention of leishmaniasis in dogs. J Am Vet Med Assoc 2010;236:1200–1206.

38. Peterson CA. Leishmaniosis, an emerging disease found in companion animals in the United States. Top Companion Anim Med 2009;24:181–188.

39. Owen SD, Oakley DA, Marryott K, et al. Transmission of visceral leishmaniasis through blood transfusions from infected English Foxhounds to anemic dogs. J Am Vet Med Assoc 2001;219:1081–1088.

40. Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000–2003. Emerg Infect Dis 2006;12:440–446.

41. Mettler M, Grimm F, Capelli G, et al. Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs. J Clin Microbiol 2005;43:5515–5519.

42. Baneth G, Koutinas AF, Solano-Gallego L, et al. Canine leishmaniasis – New concepts and insights on an expanding zoonosis: Part one. Trends Parasitol 2008;24:324–330.

43. Solano-Gallego L, Koutinas A, Miro G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniasis. Vet Parasitol 2009;165:1–18.

44. Grosjean NL, Vrable RA, Murphy AJ, Mansfield LS. Seroprevalence of antibodies against *Leishmania* spp among dogs in the United States. J Am Vet Med Assoc 2003;222:603–606.

45. Reine NJ. Infection and blood transfusion: A guide to blood donor screening. Clin Tech Small Anim Pract 2004;19:68–74.

46. Ristic M, Dawson J, Holland CJ, Jenny A. Susceptibility of dogs to infection with *Ehrlichia risticii*, causative agent of equine monocytic ehrlichiosis (Potomac horse fever). Am J Vet Res 1988;49:1497–1500.

47. Amusategui I, Tesouro MA, Kakoma I, Sainz A. Serological reactivity to *Ehrlichia canis*, Anaplasma phagocytophilum, *Neorickettsia risticii*, Borrelia burgdorferi and *Rickettsia conori* in dogs from northwestern Spain. Vector Borne Zoonotic Dis 2008;8:797–803.

48. Kakoma I, Hansen RD, Anderson BE, et al. Cultural, molecular, and immunological characterization of the etiologic agent for atypical canine ehrlichiosis. J Clin Microbiol 1994;32:170–175.

49. Hii SF, Kopp SR, Abdad MY, et al. Molecular evidence supports the role of dogs as potential reservoirs for *Rickettsia felis*. Vector Borne Zoonotic Dis 2011;11:1007–1012.

50. Hawley JR, Shaw SE, Lappin MR. Prevalence of *Rickettsia felis* DNA in the blood of cats and their fleas in the United States. J Feline Med Surg 2009;11:258–262.

51. Bern C, Kjos S, Yabsley MJ, Montgomery SP. *Trypanosoma cruzi* and Chagas’ disease in the United States. Clin Microbiol Rev 2011;24:655–681.

52. Young C, Loskoff P, Chawla A, et al. Transfusion-acquired *Trypanosoma cruzi* infection. Transfusion 2007;47:540–544.

53. Food and Drug Administration. Guidance for industry: Use of serological tests to reduce the risk of transmission of *Trypanosoma cruzi* infection in whole blood and blood components intended for transfusion. 2010 Available from: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/wcm235855.htm. Accessed June 1, 2015.

54. Steele WR, Hewitt EH, kaldun AM, et al. Donors deferred for self-reported Chagas disease history: Does it reduce risk? Transfusion 2014;54:2092–2097.

55. Barr SC, Gossett KA, Klei TR. Clinical, clinicopathologic, and parasitologic observations of trypanosomiasis in dogs infected with North American *Trypanosoma cruzi* isolates. Am J Vet Res 1991;52:954–960.

56. Bradley KK, Bergman DK, Words JP. Prevalence of American trypanosomiasis (Chagas disease) among dogs in Oklahoma. J Am Vet Med Assoc 2000;217:1853–1857.

57. Tenney TD, Curtis-Robies R, Snowden KF, Hamer SA. Shelter dogs as sentinels for *Trypanosoma cruzi* transmission across Texas, USA. Emerg Infect Dis 2014;20:1323–1326.

58. Troncarelli MZ, Camargo JB, Machado JG, et al. Leishmania spp. and/or *Trypanosoma cruzi* diagnosis in dogs from endemic and nonendemic areas for canine visceral leishmaniasis. Vet Parasitol 2009;164:118–123.

59. Enriquez GF, Cardinal MV, Orozco MM, et al. Detection of *Trypanosoma cruzi* infection in whole blood and blood components intended for transfusion. Transfusion 2007;47:540–544.

60. Al-Kharfy TM. Neonatal brucellosis and blood transfusion: Case report and review of the literature. Ann Trop Paediatr 2001;21:349–352.

61. Akcakus M, Eisel D, Cetin N, et al. Brucella *melitensis* in blood cultures of two newborns due to exchange transfusion. Turk J Pediatr 2005;47:272–274.

62. Etrem M, Kurecici AE, Aysev D, et al. Brucellosis transmitted by bone marrow transplantation. Bone Marrow Transplant 2000;26:225–226.

63. Hollett B. Canine brucellosis: Outbreaks and compliance. Theriogenology 2006;66:575–587.
64. Wanke MM. Canine brucellosis. Anim Reprod Sci 2004;82–83:195–207.
65. Keid LB, Soares RM, Vasconcellos SA, et al. A polymerase chain reaction for the detection of Brucella canis in semen of naturally infected dogs. Theriogenology 2007;67:1203–1210.
66. Keid LB, Soares RM, Vasconcellos SA, et al. A polymerase chain reaction for detection of Brucella canis in vaginal swabs of naturally infected bitches. Theriogenology 2007;68:1260–1270.
67. Keid LB, Soares RM, Vieira NR, et al. Diagnosis of canine brucellosis: Comparison between serological and microbiological tests and a PCR based on primers to 16S-23S rDNA interace. Vet Res Commun 2007;31:951–965.
68. Keid LB, Soares RM, Vasconcellos SA, et al. Comparison of agar gel immunodiffusion test, rapid slide agglutination test, microbiological culture and PCR for the diagnosis of canine brucellosis. Res Vet Sci 2009;86:22–26.
69. Kauffman LK, Bjork JK, Gallup JM, et al. Early detection of Brucella canis via quantitative polymerase chain reaction analysis. Zoonoses Public Health 2014;61:48–54.
70. Fritz CR, Kjemtrup AM. Lyme borreliosis. J Am Vet Med Assoc 2003;223:1261–1270.
71. Magorrelli LA, Anderson JF, Schreier AB. Persistence of antibodies to Borrelia burgdorferi in dogs in New York and Connecticut. J Am Vet Med Assoc 1990;196:1064–1068.
72. Wormser GP, Bittker S, Cooper D, et al. Yield of large-volume blood cultures in patients with early Lyme disease. J Infect Dis 2001;184:1070–1072.
73. Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from blood transfusion. J Infect Dis 1994;170:231–234.
74. Ginzburg Y, Kessler D, Kang S, et al. Why has Borrelia burgdorferi not been transmitted by blood transfusion? Transfusion 2013;53:2822–2826.
75. Straubinger RK. PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J Clin Microbiol 2000;38:2191–2199.
76. Sykes JE, Marks SL, Mapes S, et al. Salmon poisoning disease in dogs: 29 cases. J Vet Intern Med 2010;24:504–513.
77. Cannon AB, Luff JA, Brault AC, et al. Acute encephalitis, polyarthritis, and myocarditis associated with West Nile virus infection in dogs. J Vet Intern Med 2000;14:521–525.
78. Breitschwerdt EB, Abrams-Ogg AC, Lappin MR, et al. Molecular evidence supporting Ehrlichia canis-like infection in cats. J Vet Intern Med 2002;16:642–649.
79. Higueronzy RT, Qurollo BA, Thomas B, et al. Serological and molecular analysis of feline vector-borne anaplasmosis and ehrlichiosis using species-specific peptides and PCR. Parasit Vectors 2015;8:320–328.
80. Eberhardt JE, Neal K, Shackelford T, Lappin MR. Prevalence of select infectious disease agents in cats from Arizona. J Feline Med Surg 2001;3:328–329.
81. Sykes JE, Drazenovich NL, Ball LM, Leutenegger CM. Use of conventional and real-time polymerase chain reaction to determine the epidemiology of hemoplasma infections in anemic and nonanemic cats. J Vet Intern Med 2007;21:685–693.
82. Jensen WA, Lappin MR, Kamkar S, Reagan WJ. Use of a polymerase chain reaction assay to detect and differentiate two strains of Haemobartonella felis in naturally infected cats. Am J Vet Res 2001;62:604–608.
83. Sykes JE. Feline hemotropic mycoplasmas. J Vet Emerg Crit Care (San Antonio) 2010;20:62–69.
84. Sykes JE, Henn JB, Kasten RW, et al. Bartonella henselae infection in splenectomized domestic cats previously infected with Anaplasma phagocytophilum. J Vet Med 2001;6:159–162.
85. Lappin MR, Breitschwerdt EB, Relapsing bacteremia after blood transmission of Bartonella henselae to cats. Am J Vet Res 1997;58:492–497.
86. Nutter FB, Dubey JP, Levine JF, et al. Seroprevalences of antibodies against Bartonella henselae and Toxoplasma gondii and feline shedding of Cryptosporidium spp, Giardia spp, and Toxocara cati in feral and pet domestic cats. J Am Vet Med Assoc 2004;225:1394–1398.
87. Lappin MR, Miller W, Sellins D. Effect of doxycycline or orbifloxacin administration on Bartonella spp. and Hemoplasma assay results in naturally exposed cats. Intern J Appl Res Vet Med 2012;10:225–233.
88. Wagner JE, Ferris DH, Kier AB, et al. Experimentally induced cytazuonozoonosis-like disease in domestic cats. Vet Parasitol 1980;6:305–311.
89. Meinkoth J, Kocan AA, Whitworth L, et al. Cats surviving natural infection with Cytazuon felis: 18 cases (1997–1998). J Vet Intern Med 2000;14:521–525.
90. Breitschwerdt EB, Abrams-Ogg AC, Lappin MR, et al. Molecular evidence supporting Ehrlichia canis-like infection in cats. J Vet Intern Med 2002;16:642–649.
91. Lappin MR, Miller W, Sellins D. Effect of doxycycline or orbifloxacin administration on Bartonella spp. and Hemoplasma assay results in naturally exposed cats. Intern J Appl Res Vet Med 2012;10:225–233.
104. Goldkamp CE, Levy JK, Edinboro CH, Lachtara JL. Seroprevalences of feline leukemia virus and feline immunodeficiency virus in cats with abscesses or bite wounds and rate of veterinarian compliance with current guidelines for retrovirus testing. J Am Vet Med Assoc 2008;232:1152–1158.

105. Boudreaux CE, Lockett NN, Chemerys DN, et al. Maternal hematological and virological characteristics during early feline immunodeficiency virus (FIV) infection of cats as predictors of fetal infection and reproductive outcome at early gestation. Vet Immunol Immunopathol 2009;131:290–297.

106. Ammersbach M, Little S, Bienzle D. Preliminary evaluation of a quantitative polymerase chain reaction assay for diagnosis of feline immunodeficiency virus infection. J Feline Med Surg 2013;15:725–729.

107. Burney DP, Lappin MR, Spilker M, McReynolds L. Detection of Toxoplasma gondii parasitemia in experimentally inoculated cats. J Parasitol 1999;5:947–951.